Amgen Inc. (AMGN)

199.08
NASDAQ : Health Technology
Prev Close 203.42
Day Low/High 198.01 / 203.62
52 Wk Low/High 166.30 / 211.90
Avg Volume 3.00M
Exchange NASDAQ
Shares Outstanding 599.70M
Market Cap 121.99B
EPS 12.70
P/E Ratio 16.09
Div & Yield 5.80 (2.72%)

Latest News

Amgen and Johnson & Johnson Get a Checkup

Jefferies raises its price target for AMGN and judgement day looms for JNJ; here's our take on the health of both companies.

Video: Jim's Daily Rundown for Thursday

Jim discusses an Amgen price target boost, previews tonight's earnings release from Salesforce.com, and talks Viacom!

Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® (Rituximab)

Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® (Rituximab)

Study Evaluated Efficacy and Safety of ABP 798 Compared to Rituxan in Patients With Non-Hodgkin's Lymphoma

Amgen Declines Following Mizuho Downgrade to Neutral

Amgen Declines Following Mizuho Downgrade to Neutral

Amgen's rating is lowered at Mizuho but its price target gets raised to $212.

Weekly Roundup

Markets were whipsawed this week by trade-war jitters and the U.S yield-curve inversion.

Video: AAP Daily Rundown for Friday

Jeff fills in for Jim to discuss Nvidia's earnings, analyst activity around Burlington Stores, and more!

Fear Not the Curve, Sizing Up Earnings and Ways to Play Amgen: Market Recon

Fear Not the Curve, Sizing Up Earnings and Ways to Play Amgen: Market Recon

Understanding yourself and the investing environment you are in are keys to avoiding panic brought on by fear.

Who Are the Highest-Paid Golfers in 2019?

Who Are the Highest-Paid Golfers in 2019?

2019 has been a banner year for professional golf, and a profitable one for these top linksters.

Amgen Climbs After Winning Patent Case on Enbrel

Amgen Climbs After Winning Patent Case on Enbrel

Amgen's patents for Enbrel likely to be protected until 2029.

Video: Jim's Daily Rundown for Monday

Jim discusses this morning's profit-taking cash raising effort, Amgen's successful defense of Enbrel, semiconductors, and more!

Weekly Roundup

We are staying the course, using bouts of panic to buy up the stocks of high-quality companies on discounts.

Amgen Wins Patent Case On Enbrel® (etanercept)

Amgen Wins Patent Case On Enbrel® (etanercept)

Court Upholds Validity of Patent Claims Directed to Enbrel

Bullpen Update

These companies already posted strong earnings this season and are not economically sensitive.

Real Money Post-Industrial Average Leads Major Indexes So Far for Year

Real Money Post-Industrial Average Leads Major Indexes So Far for Year

In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.

Another Check on Every Portfolio Name: Where Would We Buy?

We are taking a moment to provide price levels for nearly every position in the portfolio.

Amgen Changes the Narrative With Cancer Drug Breakthrough

Amgen Changes the Narrative With Cancer Drug Breakthrough

Amgen built on the momentum at a recent conference on its Q2 earnings call as management highlighted recent positive developments for its KRAS inhibitor drug.

Weekly Roundup

While the trade war is clearly intensifying, we are viewing the market through a buyers' lens, waiting for pullbacks that improve our basis.

Amgen Announces 2019 Third Quarter Dividend

Amgen Announces 2019 Third Quarter Dividend

THOUSAND OAKS, Calif., Aug.

Amgen Stock Gains as Analysts Assess Solid Earnings

Amgen Stock Gains as Analysts Assess Solid Earnings

Amgen shares are up the day after it reported results, but not all analysts are cheering with abandon.

Apple, Federal Reserve, AMD, General Electric, Qualcomm - 5 Things You Must Know

Apple, Federal Reserve, AMD, General Electric, Qualcomm - 5 Things You Must Know

U.S. stock futures rise, getting a lift from Apple, which was higher after the tech giant beat earnings expectations, and as Wall Street prepares for the first interest rate cut from the Federal Reserve in more than a decade; GE, Qualcomm and Humana report earnings.

Putting Amgen's Q2 Earnings Under the Microscope

Here we break down the numbers of some of the company's top drugs, but we now only have 175 shares remaining in this tag end of a position, as there are better health care stocks in the market right now.

Amgen Reports Second Quarter 2019 Financial Results

Amgen Reports Second Quarter 2019 Financial Results

THOUSAND OAKS, Calif., July 30, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the second quarter of 2019.

Earnings Previews for Companies Set to Report Later This Week

Portfolio names Lam Research and Twilio report Wednesday, Dupont and Shopify on Thursday.

Video: Jim's Daily Rundown for Tuesday

Jim discusses earnings from BP and Mastercard, previews tonight's earnings from Apple and Amgen, and more!

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.

Capital One, Apple, AMD, Beyond Meat, Federal Reserve - 5 Things You Must Know

Capital One, Apple, AMD, Beyond Meat, Federal Reserve - 5 Things You Must Know

U.S. stock futures point lower on Tuesday, the first day of a critical two-day meeting of the Federal Reserve, and ahead of quarterly earnings from tech giant Apple; the earnings calendar also includes reports from Merck, Procter & Gamble, Mastercard and AMD; Capital One says a hacker got access to the personal information of more than 100 million of its credit card customers and applicants.

A Look Into Tuesday's Earnings

Portfolio names Mastercard, BP, Apple and Amgen will report quarterly results Tuesday.

Weekly Roundup

Markets see solid performance during busy earnings season week.

TheStreet Quant Rating: A- (Buy)